The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1α,25- dihydroxyvitamin D2 as therapeutic agents for prostate cancer
- Tai C. Chen(corresponding author),
- Gary G. Schwartz,
- Kerry L. Burnstein,
- ,
- Michael F. Holick
- Boston University,
- Wake Forest University,
- University of Miami
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Prostate cancer cells contain specific receptors [vitamin D receptors (VDRs)] for 1α,25-dihydroxyvitamin D<sub>3</sub> (1α,25(OH)<sub>2</sub>D<sub>3</sub>), which is known to inhibit the proliferation and invasiveness of these cells. These findings support the use of 1α,25(OH)<sub>2</sub>D<sub>3</sub> for prostate cancer therapy. However, because 1α,25(OH)<sub>2</sub>D<sub>3</sub> can cause hypercalcemia, analogues of 1α,25(OH)<sub>2</sub>D<sub>3</sub> that are less calcemic but that exhibit potent antiproliferative activity would be attractive as therapeutic agents. We investigated the effects of two different types of less calcemic vitamin D compounds, 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] and 19-nor-1α,25-dihydroxyvitamin D<sub>2</sub> [19-nor-1,25(OH)<sub>2</sub>D<sub>2</sub>], and compared their activity to 1α,25(OH)<sub>2</sub>D<sub>3</sub> on (a) the proliferation of primary cultures and cell lines of human prostate cancer cells; and (b) the transactivation of the VDRs in the androgen-insensitive PC-3 cancer cell line stably transfected with VDR (PC-3/VDR). 19-nor-1α,25(OH)<sub>2</sub>D<sub>2</sub>, an analogue of 1α,25(OH)<sub>2</sub>D<sub>3</sub> that was originally developed for the treatment of parathyroid disease, has been shown to be less calcemic than 1α,25(OH)<sub>2</sub>D<sub>3</sub> in clinical trials. Additionally, we recently showed that human prostate cells in primary culture possess 25(OH)D<sub>3</sub>-1α-hydroxylase, an enzyme that hydroxylates the inactive prohormone, 25(OH)D<sub>3</sub>, to the active hormone, 1α,25(OH)<sub>2</sub>D<sub>2</sub>, intracellularly. We reasoned that the hormone that is formed intracellularly would inhibit prostate cell proliferation in an autocrine fashion. We found that 1α,25(OH)<sub>2</sub>D<sub>3</sub> and 19-nor-1α,25(OH)<sub>2</sub>D<sub>2</sub> caused similar dose-dependent inhibition in the cell lines and primary cultures in the [<sup>3</sup>H]thymidine incorporation assay and that both compounds were significantly more active in the primary cultures than in LNCaP cells. Likewise, 25(OH)D<sub>3</sub> had inhibitory effects comparable to those of 1α,25(OH)<sub>2</sub>D<sub>3</sub> in the primary cultures. In the chloramphenicol acetyltransferase (CAT) reporter gene transactivation assay in PC-3/VDR cells, 1α,25(OH)<sub>2</sub>D<sub>3</sub> and 19-nor-1α,25(OH)<sub>2</sub>D<sub>2</sub> caused similar increases in CAT activity between 10<sup>-11</sup> and 10<sup>-9</sup> M. Incubation of PC-3/VDR cells with 5 x 10<sup>-8</sup> 25(OH)D<sub>3</sub> induced a 29-fold increase in CAT activity, similar to that induced by 10<sup>-8</sup> M 1α,25(OH)<sub>2</sub>D<sub>3</sub>. In conclusion, our data indicate that 25(OH)D<sub>3</sub> and 19-nor-1α,25(OH)<sub>2</sub>D<sub>2</sub> represent two different solutions to the problem of hypercalcemia associated with vitamin D-based therapies: 25(OH)D<sub>3</sub> requires the presence of 1α-hydroxylase, whereas 19-nor- 1α,25(OH)<sub>2</sub>D<sub>2</sub> does not. Both drugs are approved for human use and may be good candidates for human clinical trials in prostate cancer.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 901-908 (8 pages)Journal (Volume, Issue Number)
Clinical Cancer Research (Volume 6, Issue 3)Publication milestones
- Published - 03/2000
Publication status
Published - 03/2000
ISSN
1078-0432Publication IDs
- Scopus: 0034061507
- PubMed: 10741714
Access to documents
Publication metrics
Metrics
SciVal
citations
99
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
FWCI
2.11
SciVal
Author count
5
SciVal
Paper percentile
93
SciVal
Top percentile
10
PlumX
Captures
24
Social media
1
Citation count
111
Funding Details
FunderFunding number
NCI
R01CA068565
